Summary
Global Markets Direct’s, ‘Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the Sarepta Therapeutics, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Sarepta Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Sarepta Therapeutics, Inc.
- The report provides overview of Sarepta Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Sarepta Therapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Sarepta Therapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Sarepta Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Sarepta Therapeutics, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Sarepta Therapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Sarepta Therapeutics, Inc. Snapshot 7
Sarepta Therapeutics, Inc. Overview 7
Key Information 7
Key Facts 7
Sarepta Therapeutics, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Sarepta Therapeutics, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Sarepta Therapeutics, Inc. - Pipeline Products Glance 13
Sarepta Therapeutics, Inc. - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Sarepta Therapeutics, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Sarepta Therapeutics, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Sarepta Therapeutics, Inc. - Drug Profiles 18
eteplirsen 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
SRP-4053 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
SRP-4045 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
AVI-7288 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
radavirsen 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PMO-25 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
SRP-4008 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
SRP-4044 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
SRP-4050 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
SRP-4052 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
SRP-4055 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Antisense Oligonucleotide for Acinetobacter baumannii Infections 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Antisense Oligonucleotide for Methicillin Resistant Staphylococcus Aureus Infections 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Antisense Oligonucleotide to Activate Lamin A for Progeria 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Antisense Oligonucleotides for Infectious Diseases 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Bacterial PPMO 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Viral PMO-X 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Sarepta Therapeutics, Inc. - Pipeline Analysis 49
Sarepta Therapeutics, Inc. - Pipeline Products by Target 49
Sarepta Therapeutics, Inc. - Pipeline Products by Route of Administration 50
Sarepta Therapeutics, Inc. - Pipeline Products by Molecule Type 51
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action 52
Sarepta Therapeutics, Inc. - Recent Pipeline Updates 53
Sarepta Therapeutics, Inc. - Dormant Projects 66
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products 67
Discontinued Pipeline Product Profiles 67
AVI-4065 67
AVI-6002 67
AVI-7537 67
Sarepta Therapeutics, Inc. - Company Statement 68
Sarepta Therapeutics, Inc. - Locations And Subsidiaries 71
Head Office 71
Other Locations & Subsidiaries 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 72
Disclaimer 73
List of Tables
Sarepta Therapeutics, Inc., Key Information 7
Sarepta Therapeutics, Inc., Key Facts 7
Sarepta Therapeutics, Inc. - Pipeline by Indication, 2016 9
Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016 11
Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 12
Sarepta Therapeutics, Inc. - Pre-Registration, 2016 13
Sarepta Therapeutics, Inc. - Phase II, 2016 14
Sarepta Therapeutics, Inc. - Phase I, 2016 15
Sarepta Therapeutics, Inc. - Preclinical, 2016 16
Sarepta Therapeutics, Inc. - Discovery, 2016 17
Sarepta Therapeutics, Inc. - Pipeline by Target, 2016 49
Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016 50
Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016 51
Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 52
Sarepta Therapeutics, Inc. - Recent Pipeline Updates, 2016 53
Sarepta Therapeutics, Inc. - Dormant Developmental Projects,2016 66
Sarepta Therapeutics, Inc. - Discontinued Pipeline Products, 2016 67
Sarepta Therapeutics, Inc., Other Locations 71
Sarepta Therapeutics, Inc., Subsidiaries 71
List of Figures
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016 9
Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016 11
Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 12
Sarepta Therapeutics, Inc. - Pipeline by Top 10 Target, 2016 49
Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016 50
Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016 51
Sarepta Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 52
